Imperial College London

Dr Sue Wilson

Faculty of MedicineDepartment of Brain Sciences

Honorary Senior Research Fellow
 
 
 
//

Contact

 

sue.wilson

 
 
//

Location

 

Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Wilson:2004,
author = {Wilson, SJ and Bailey, JE and Rich, AS and Adrover, M and Potokar, J and Nutt, DJ},
journal = {Eur.Neuropsychopharmacol.},
pages = {367--372},
title = {Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram},
url = {pm:15336297},
volume = {14},
year = {2004}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - BACKGROUND: SSRIs suppress rapid eye movement (REM) sleep, probably by increasing serotonin in the brainstem, and also increase sleep fragmentation. Although in the UK, paroxetine (PAR) and citalopram (CIT) have recommended doses of 20 mg/day for the treatment of depression, the recommended dose of CIT in USA is higher (40 mg). If similar doses of PAR and CIT have similar effects on central serotonin then they should have similar effects on sleep measures in volunteers. METHOD: This was a randomised, double blind placebo controlled crossover study in 12 healthy volunteers. Subjects took PAR 20 mg mane, CIT 20 mg mane or placebo mane for 3 days and sleep was recorded overnight at home on the third night. Standard measures of sleep were derived. RESULTS: REM sleep was significantly suppressed and sleep fragmentation increased by both drugs. Measures of REM sleep and sleep continuity previously found to be altered by SSRIs were considered together and compared with placebo as a 'serotonin response'; this was significantly greater in the PAR group. CONCLUSIONS: Sleep effects typical of SSRIs were greater with PAR 20 mg/day than CIT 20 mg/day, suggesting greater effects on 5HT uptake blockade
AU - Wilson,SJ
AU - Bailey,JE
AU - Rich,AS
AU - Adrover,M
AU - Potokar,J
AU - Nutt,DJ
EP - 372
PY - 2004///
SP - 367
TI - Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram
T2 - Eur.Neuropsychopharmacol.
UR - pm:15336297
VL - 14
ER -